AngioDynamics Q4 sales beat estimates on Med Tech strength
ANGO•Key growth drivers
- NanoKnife growth - NanoKnife sales rose 64.5% in Q4, driven by 47% growth in probes and 132.5% growth in capital sales, supported by new reimbursement milestones and positive clinical data.
- Auryon platform - Auryon sales increased 14.4% year over year, contributing to Med Tech segment growth.
- Gross margin improvement - Gross margin rose 130 basis points to 54.0%, mainly due to favorable pricing and a shift toward higher-margin Med Tech products.
Fiscal 2027 outlook
AngioDynamics sees fiscal 2027 net sales between $336 million and $341 million.
The company expects Med Tech net sales growth of 12%–15% and Med Device net sales growth flat.
AngioDynamics expects gross margin of 54%–55% and adjusted EBITDA of $13 million–$16 million for fiscal 2027.
